Infinity Adds Two New Members To Board of Directors

Xconomy Boston — 

Infinity Pharmaceuticals, (NASDAQ: INFI) a Cambridge, MA-based developer of cancer drugs, said today it has added two new members to its board, Martin Babler and Ian Smith. Babler is CEO of Talima Therapeutics, a privately-held drug delivery company in San Carlos, CA, and previously held senior marketing positions at Genentech (NYSE: DNA). Smith is chief financial officer of Vertex Pharmaceuticals (NASDAQ: VRTX). The company’s board now has 12 members, according to its web site.